[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acquired-von-willebrand-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acquired-von-willebrand-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100643230","flow-based-platelet-function-assessment-using-total-thrombus-formation-analysis-system-t-tas-and-early-bleeding-after-cardiac-surgery-with-cardiopulmonary-bypass-cpb-100643230",false,"NCT07619261","Flow-Based Platelet Function Assessment Using Total Thrombus-Formation Analysis System (T-TAS) and Early Bleeding After Cardiac Surgery With Cardiopulmonary Bypass (CPB)","Prospective Observational Study of Flow-Based Platelet Function Using T-TAS and Early Bleeding After Cardiopulmonary Bypass in Adult Cardiac Surgery","TTAS-CPB","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Undergoing elective or urgent cardiac surgery requiring cardiopulmonary bypass\n3. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Cardiac surgery performed without cardiopulmonary bypass\n2. Emergency cardiac surgery\n3. Preoperative anticoagulation not reversed at the time of surgery\n4. Refusal or withdrawal of informed consent\n5. Known pregnancy","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","2 Days","OBSERVATIONAL","The goal of this observational study is to learn how flow-based platelet function measured with the Total Thrombus-formation Analysis System (T-TAS) relates to early postoperative bleeding in adults undergoing cardiac surgery with cardiopulmonary bypass. The study will also evaluate how T-TAS changes during the perioperative period and how it compares with standard coagulation and platelet function tests.\n\nThe main questions it aims to answer are:\n\nIs lower post-cardiopulmonary bypass T-TAS Platelet-chip (PL-chip) thrombus formation associated with increased postoperative chest tube drainage during the first 12 hours after surgery? How do T-TAS parameters change before surgery, immediately after cardiopulmonary bypass, and 24 hours after surgery? Are abnormal T-TAS results associated with blood transfusion requirements, major bleeding, re-exploration for bleeding, and length of stay in the intensive care unit and hospital? Does T-TAS provide complementary information compared with standard coagulation tests, von Willebrand factor (vWF) measurements, platelet aggregometry, and viscoelastic testing?\n\nParticipants will:\n\nUndergo blood sampling at three predefined perioperative time points:\n\nbefore anesthesia induction, immediately after cardiopulmonary bypass and heparin reversal with protamine, and 24 hours after surgery Have T-TAS testing, standard laboratory coagulation tests, vWF testing, platelet aggregometry, and viscoelastic testing performed on collected samples Have clinical, surgical, transfusion, and postoperative bleeding data collected during their hospital stay\n\nThe study is observational and does not require changes to routine clinical care or perioperative management.",[26,27,28,29,30],"Perioperative Bleeding","Coagulopathy During Cardiac Surgery","Platelet Dysfunction","Cardiac Surgery","Acquired Von Willebrand Disease",[29,32,33,34,35,36,37,38,39,40],"Total Thrombus formation Analysis System (T-TAS)","Platelet Function","Postoperative Bleeding","Hemostasis","Blood Transfusion","ROTEM","Thrombus Formation","Cardiopulmonary Bypass (CPB)","von Willebrand Factor (vWF)","NOT_YET_RECRUITING","2026-06-08",{"date":44,"type":45},"2026-06-10","ACTUAL",{"date":47,"type":21},"2026-09-15",{"date":49,"type":21},"2027-02-15",{"name":51,"class":52},"Hospital de la Santa creu i Sant Pau - Barcelona","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100620468","endothelial-colony-forming-cells-in-patients-with-vwd-avws-and-healthy-subjects-100620468","NCT07358013","Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects","Isolation and Characterization of Endothelial Colony Forming Cells (ECFCs) in Patients Diagnosed With Von Willebrand Disease, Acquired Von Willebrand Syndrome and Healthy Subjects","ECFCs\u002F2022","Inclusion Criteria for patients:\n\nPatients with von Willebrand disease (VWD) or acquired von Willebrand syndrome (AVWS)\n\nAge ≥ 16 years.\n\nPrevious diagnosis of von Willebrand disease or acquired von Willebrand syndrome, defined as one of the following:\n\nGroup A - Type 1 VWD:\n\nVWF levels ≤ 30 IU\u002FdL, regardless of bleeding history, or\n\nVWF levels ≤ 0.50 IU\u002FmL in the presence of abnormal bleeding.\n\nGroup B - Congenital or acquired VWD (VWD or AVWS):\n\nDiagnosis of congenital or acquired VWD, with or without gastrointestinal bleeding.\n\nGroup C - Subgroup study (Type 2A VWD):\n\nOne patient with type 2A VWD selected for a dedicated sub-study involving allele-specific siRNA silencing of the mutant allele.\n\nAbility and willingness to provide written informed consent.\n\nFor patients without prior molecular characterization: willingness to undergo VWF gene sequencing and to sign the related informed consent.\n\nInclusion criteria for healthy volunteers\n\n* No prior diagnosis of VWD, bleeding disorders, or thrombotic disorders.\n* Willingness to donate blood for study procedures.\n* Ability and willingness to provide written informed consent.\n* Age ≥ 18 years.\n\nExclusion criteria for both patients and healthy volunteers:\n\n* Pregnancy.\n* Anemia, as determined at screening or based on medical history.",true,"16 Years",{"count":64,"type":21},48,"The goal of this observational study is to learn how endothelial colony-forming cells (ECFCs) behave in people with von Willebrand disease (VWD), acquired von Willebrand syndrome (AVWS), and in healthy individuals.",[67,30],"Von Willebrand Disease (VWD)",[69,70,71,72],"von Willebrand disease","von Willebrand factor","ex vivo","endothelial colony forming cells (ECFCs)","RECRUITING","2026-01-13",{"date":76,"type":45},"2026-01-22",{"date":78,"type":45},"2023-11-11",{"date":80,"type":21},"2028-05-31",{"name":82,"class":52},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",1]